|Bid||107.30 x 800|
|Ask||107.75 x 800|
|Day's Range||107.10 - 108.25|
|52 Week Range||79.11 - 121.53|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||29.05|
|Earnings Date||Oct 28, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||5.20 (4.83%)|
|Ex-Dividend Date||Oct 14, 2021|
|1y Target Est||125.96|
The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy.
Whether the news is good or bad, you can take advantage of it if you understand why you're involved in a stock in the first place.
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.